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OBJECTIVES We sought to determine whether the changing practice of interventional cardiology has been
associated with improved outcomes for women, and how these outcomes compare with those
for men.
BACKGROUND Previous work from the early 1990s suggested women are at a higher risk than men for
adverse outcomes after percutaneous coronary interventions (PCIs).
METHODS From 1994 to 1999 data were collected on 33,666 consecutive hospital admissions for a PCI
in Northern New England. Multivariate models were used to adjust for differences in
case-mix across year of procedure when comparing outcomes. Direct standardization was used
to calculate adjusted rates.
RESULTS From 1994 to 1999, the case-mix worsened for both women and men, although women had
more co-morbidities than did men throughout the period. Stent use increased over time
(75% in 1999). Concomitantly, the need for emergency coronary artery bypass graft surgery
(CABG) decreased significantly (ptrend  0.001; in 1999: 0.06% for women, 0.05% for men).
Although the emergency CABG rates were higher for women at the beginning of the study,
by the end, they were comparable (adjusted odds ratio 1.34, 95% confidence interval 0.76 to
2.38, p  0.315). The myocardial infarction (MI) rates decreased over time for both women
(by 29.7%, ptrend  0.378) and men (by 37.6%, ptrend  0.009) and did not differ by gender.
The mortality rates did not decrease significantly over time and were not significantly different
between the genders (mean 1.21% for women, 1.06% for men; p  0.096).
CONCLUSIONS Concurrent with the changing practice of PCI, and despite treating sicker patients, there have
been important improvements in post-PCI CABG and MI rates for women, as well as for
men. Unlike in earlier years, there are no longer significant differences in outcomes by
gender. (J Am Coll Cardiol 2002;40:2092–101) © 2002 by the American College of
Cardiology Foundation
Women undergoing a percutaneous coronary intervention
(PCI) may face a higher risk of adverse outcomes than do
men. This was our experience in Northern New England in
the early 1990s, when we reported (1) a higher risk of
in-hospital death after PCI for women than for men (odds
ratio [OR] 1.64, 95% confidence interval [CI] 1.09 to 2.47).
Although the published data on this topic are discrepant
(2–11), there is reason to suspect that outcomes could be
worse for women than for men. A number of studies suggest
that women undergo PCIs later in the course of their
disease, present with more co-morbidities, and have a more
technically difficult anatomy to revascularize (12–18).
Most studies reporting on the process and outcomes of
PCI for women versus men date from the early to mid-
1990s. Since that time, the practice of interventional cardi-
ology has changed (19). Catheters have been improved; they
have better compliance characteristics and lower profiles and
allow for perfusion distal to the balloon. Alternative devices
for lesion-specific treatment are available. Coronary stents
for “bail-out” in the setting of abrupt closure or suboptimal
results are widely used, and the advent of high-pressure
inflation and intravascular ultrasound has lowered the asso-
ciated risk of acute thrombus formation. Clinical trials and
ever-growing experience have taught cardiologists more
about case selection and the use of adjunctive medical
therapy, particularly platelet glycoprotein (GP) IIb/IIIa
receptor inhibitors. Given all these changes, the outcomes
for women after PCI may be improving. To determine
whether this is true, we examined our 1994–1999 Northern
New England PCI registry data to characterize the current
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practice of interventional cardiology in women, to compare
it to past practice, and to contrast it to the experience of
men.
METHODS
The Northern New England Cardiovascular Disease Study
Group is a voluntary research consortium composed of
clinicians, research scientists, and hospital administrators at
five institutions in Maine, New Hampshire, and Vermont,
which are providers of coronary revascularization in the
region, as well as one Massachusetts-based institution. The
intent of the group is to foster continuous improvement in
the quality of care of patients with cardiovascular disease in
Northern New England by pooling process and outcome
data and its timely feedback to clinicians (20,21).
Between January 1, 1994 and December 31, 1999, data
were collected on 33,666 consecutive hospital admissions
(10,977 [32.6%] women and 22,689 [67.4%] men) during
which PCI was performed. Information was collected in the
following categories: demographics; medical history; pri-
mary indication for PCI; priority at PCI; therapy before,
during, and after the procedure; cardiac anatomy and
function; procedural information; and in-hospital outcomes,
including death, emergency coronary artery bypass graft
surgery (CABG), nonemergency CABG, or new myocar-
dial infarction (MI), defined as chest pain, diaphoresis,
dyspnea, and/or hypotension associated with the develop-
ment of new Q waves or ST-TW–segment changes and a
rise in creatine kinase (CK) to at least twice the normal
value, with a positive CK-MB fraction. Clinical success was
defined as one or more attempted lesion(s) successfully
dilated and no adverse clinical outcomes. Adverse clinical
outcomes included any hospital death, emergency or non-
emergency CABG, or postprocedural MI. The failure to
cross or engage at least one lesion was not considered an
adverse clinical outcome but would prevent a procedure
from being labeled a clinical success.
The number of patients in the data set was verified using
hospital discharge data supplemented by cardiac catheter-
ization laboratory logs. Information was obtained for any
missing procedure. The outcomes of death and CABG were
validated from the hospital discharge data set and a review
of the medical records through 1998. Myocardial infarction
was validated only for 1994 by a review of the medical
records.
All analyses were carried out using Statistical Analysis
Software, release 6.11 (SAS, Cary, North Carolina) or
STATA Statistical Software, release 5.0 (Stata Corp, Col-
lege Station, Texas). For the purpose of analysis, the registry
experience was divided into three eras based on an exami-
nation of changing practice patterns in the use of stents
within the region (Fig. 1A) and our knowledge of how the
indication for stenting changed over time: 1994 to June
1995  early stent experience; July 1995 to 1997 
provisional stenting experience; 1998 to 1999  current
stent experience. Logistic regression (22) was used to assess
whether changes in case-mix and outcomes differed over
time, reported as ptrend, except for the ordinal variables of
indication, priority, and lesion type, where the Mantel-
Haenszel chi-squared statistic was used. The p value for
trend is useful for detecting any linear relationship between
exposure and disease. Multivariate models were used to
adjust for differences in case-mix and severity of illness
across year of procedure when comparing outcomes. All
variables demonstrating a univariate association with the
dependent variable of interest at p  0.10 were considered
potential independent variables for inclusion in the multi-
variate analyses. To determine whether there was a signif-
icant change in outcomes over time, a variable for year of
procedure was forced into the multivariate model. Direct
standardization (23) was used to calculate adjusted rates.
Comparisons of outcomes in women versus men are re-
ported as ORs, with men as the referent group, calculated
using standard statistical methods (24), with 95% CIs.
RESULTS
The average age of women undergoing PCI increased by 0.6
years during the mid-1990s, with a slight increase in those
80 years old in 1998 to 1999 (Table 1). In addition, the
prevalence of vascular disease, renal failure, previous
CABG, congestive heart failure (CHF), ejection fraction
40%, left ventricular end-diastolic pressure (LVEDP)
18 mm Hg, and significant left main coronary artery
(LMCA) disease all increased. The prevalence of cigarette
smoking decreased, although it remained high at 24.3% in
1998–1999, as did the prevalence of previous MI, previous
PCI, and multivessel coronary artery disease. Average body
surface area (BSA), creatinine, diabetes mellitus (DM), and
chronic obstructive pulmonary disease (COPD) all re-
mained relatively stable (1% change) over time. In men,
the average age increased by two years over time, with an
increase of 1.1% in those 80 years old. The prevalence of
DM, vascular disease, COPD, renal failure, previous
CABG, CHF, ejection fraction 40%, LVEDP 18 mm
Hg, and LMCA disease increased over the study period,
whereas the other patient characteristics remained relatively
stable. Compared with men, women were approximately
five to six years older at the time of their PCI, and there
Abbreviations and Acronyms
BSA  body surface area
CABG  coronary artery bypass graft surgery
CHF  congestive heart failure
COPD  chronic obstructive pulmonary disease
DM  diabetes mellitus
GP  glycoprotein
LMCA  left main coronary artery
PCI  percutaneous coronary intervention
LVEDP  left ventricular end-diastolic pressure
MI  myocardial infraction
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were more women80 years old. As expected, women were
smaller than men and had lower creatinine levels. Women
had more DM, vascular disease, COPD, renal failure, and
CHF and were more likely to have LVEDP 18 mm Hg,
as compared with men. Women were less likely to smoke
and have a history of MI, previous PCI, previous CABG,
and LMCA and three-vessel disease.
In women, procedural indications and priority (Table 2)
remained relatively stable over time, with the exception of a
small decrease in unstable angina and an increase in stable
angina and primary PCI for MI, the last of which was
accompanied by an increase in emergent procedures. Even
in more recent years, 10% of procedures in women
involved more than one lesion, although lesion complexity
increased, with a higher percentage of lesions being classi-
fied as American College of Cardiology (ACC) type B2 and
Figure 1. (A to F) Changing risk-adjusted in-hospital outcomes for women and men undergoing percutaneous coronary intervention (PCI) in Northern
New England from 1994 to 1999. CABG  coronary artery bypass graft surgery; MI  myocardial infarction.
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Table 1. Clinical Characteristics of Women and Men Undergoing a PCI in Northern
New England by Era of Stenting
Characteristic
Stent Era
ptrend*
Early
(1994–6/95)
Provisional
(7/95–1997)
Current
(1998–1999)
Women (n) 2,310 4,684 3,983
Men (n) 4,879 9,753 8,057
Mean age (yrs)
Women 65.3 65.9 65.9  0.001
Men 59.3 60.1 61.3  0.001
Age  80 yrs (%)
Women 9.5 9.9 11.4  0.001
Men 3.8 4.1 4.9  0.001
Mean BSA (m2)
Women 1.85 1.84 1.82  0.001
Men 2.00 2.03 2.06  0.001
Mean creatinine (mg/dl)
Women 1.0 1.0 1.0 0.551
Men 1.1 1.1 1.1  0.001
Co-morbidities (%)
Smoker
Women 27.2 26.1 24.3  0.001
Men 31.9 36.0 32.7  0.001
Diabetes mellitus
Women 29.1 28.9 29.8 0.824
Men 17.8 19.3 20.7  0.001
Vascular disease
Women 12.1 12.4 14.8  0.001
Men 8.7 9.5 11.6  0.001
COPD
Women 10.1 10.5 10.9  0.001
Men 8.3 8.6 9.2  0.001
Renal failure
Women 1.6 3.0 4.8  0.001
Men 1.4 2.5 4.2  0.001
Previous cardiac history (%)
Previous MI
Women 23.1 20.8 19.5  0.001
Men 28.0 24.8 23.3  0.001
Previous PCI
Women 27.8 25.0 24.4 0.011
Men 31.8 26.0 26.6  0.001
Previous CABG
Women 11.3 12.7 13.5  0.001
Men 14.2 16.7 18.7  0.001
Congestive heart failure
Women 6.0 9.5 12.2  0.001
Men 3.9 6.0 7.4  0.001
Cardiac anatomy and function (%)
Ejection fraction 40%
Women 3.7 4.8 5.7 0.336
Men 4.0 5.9 6.5  0.001
LVEDP 18 mm Hg
Women 14.8 14.3 16.6 0.079
Men 12.2 12.3 13.8 0.344
50% LMCA disease
Women 1.6 2.8 3.6  0.001
Men 2.4 4.1 5.1  0.001
Multivessel disease
Women 33.8 31.0 31.5  0.001
Men 36.4 33.7 36.8  0.001
*Analysis of variance for continuous variables.
BSA  body surface area; CABG  coronary artery bypass graft surgery; COPD  chronic obstructive pulmonary disease;
LMCA  left main coronary artery; LVEDP  left ventricular end-diastolic pressure; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
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Table 2. Indication, Priority, and Procedural Characteristics of Women and Men Undergoing a
PCI in Northern New England by Era of Stenting
Characteristic
Stent Era
ptrend
Early
(1994–6/95)
Provisional
(7/95–1997)
Current
(1998–1999)
Women (n) 2,310 4,684 3,983
Men (n) 4,879 9,753 8,057
Indication for first procedure (%)
Women
Stable angina 19.3 18.2 20.9 0.020
Unstable angina 74.3 75.6 71.6
Primary therapy for MI 3.7 4.2 5.4
Cardiogenic shock 0.4 0.8 1.1
Other 2.3 1.2 1.1
Men
Stable angina 23.8 24.4 26.2  0.001
Unstable angina 68.6 68.5 65.6
Primary therapy for MI 4.4 5.6 6.8
Cardiogenic shock 0.6 0.5 0.6
Other 2.6 0.9 0.8
Priority for first procedure (%)
Women
Emergent 8.3 7.9 9.3 0.086
Urgent 61.0 60.7 61.8
Nonurgent 30.7 31.4 28.9
Men
Emergent 9.3 9.2 10.0  0.001
Urgent 53.2 54.5 56.8
Nonurgent 37.6 36.3 33.2
Lesion characteristics (%)
2 lesions attempted
Women 7.4 7.8 8.2  0.001
Men 6.9 7.8 10.0  0.001
Proximal LAD attempted
Women 17.8 17.3 17.1 0.072
Men 17.6 16.6 15.3  0.001
Graft attempted
Women 5.0 3.8 5.5  0.001
Men 5.6 7.1 7.8  0.001
Lesions types
Women
A 42.5 29.8 20.0  0.001
B1 38.8 39.2 40.6
B2 11.4 22.3 28.3
C 7.3 8.8 11.2
Men
A 38.5 28.0 17.7  0.001
B1 40.9 39.9 40.4
B2 12.2 22.7 29.5
C 8.4 9.4 12.4
Devices (%)
Stent
Women 3.9 45.8 72.4  0.001
Men 4.1 49.7 78.6  0.001
Directional atherectomy
Women 7.8 2.0 1.5  0.001
Men 10.3 3.6 1.7  0.001
Rotational atherectomy
Women 4.1 7.6 10.7  0.001
Men 3.3 5.4 7.7  0.001
Glycoprotein IIb/IIIa inhibitors (%)
Women 0 7.2 20.3  0.001
Men 0.1 8.8 22.8  0.001
LAD  left anterior descending coronary artery; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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C in more recent years. The biggest procedure-related
change over time in women was in the use of devices and
GP IIb/IIIa inhibitors. There was a marked increase in the
use of stents (Fig. 1A), such that by 1999, 75.9% of women
undergoing PCI received one or more stent(s). Although
directional atherectomy was rarely used in recent years,
rotational atherectomy use increased to 10.7% in 1998 to
1999. The use of GP IIb/IIIa inhibitors was largely con-
fined to more recent years, and they were used selectively in
20.3% of patients. The temporal changes seen over time in
women were largely parallel to those in men. However,
compared with men, women were more likely to present
with unstable angina, require an urgent procedure, undergo
rotational atherectomy, or have an intervention on a prox-
imal left anterior descending coronary lesion, and they were
less likely to undergo a graft PCI, have a stent placed, or
receive a GP IIb/IIIa inhibitor. There was no gender-
related difference in stent use after controlling for patient
age and BSA (OR 1.04, 95% CI 0.99 to 1.08).
Procedural outcomes, both unadjusted and adjusted, are
summarized in Tables 3 and 4, respectively (by era of stenting),
and are shown by year in Figure 1 to help clarify trends.
Controlling for differences in case-mix over time made little
difference in the point estimates of most outcomes, except for
in-hospital mortality. When not specified, we refer to adjusted
rates. In women, there was a clinically important and statisti-
cally significant decrease in the rates of emergency and non-
emergency CABG during the 1990s. The overall CABG rate
decreased by 72.3% for women (ptrend  0.001), with an
absolute decrease of 2.45%. The MI rates decreased by 27.7%
from the periods 1994 to June 1995 and July 1995 to 1997 and
then leveled off (ptrend  0.378). There was not a significant
trend toward a lower postprocedural in-hospital mortality rate
during the study period (average mortality 1.21%; ptrend 
0.846), although mortality in the current era of stenting was
20% lower than that in the era of provisional stenting. As a
consequence, largely due to decreased rates of CABG and MI
and a small decline in the inability to cross or engage lesions,
clinical success rates improved by 4.41% during the second half
of the decade, reaching 93.45% (ptrend  0.001) in the period
1998 to 1999.
The CABG rates for men in this period decreased by 75%
(ptrend  0.001), with an absolute decrease of 2.49%. The
MI rates remained stable until 1998 to 1999, when they
decreased by 35% to 1.36% in 1998 to 1999 (ptrend 
0.001). Compared with women, the mortality rates for men
remained relatively constant in the eras of early and provi-
sional stenting, decreasing by 37.5% only in the current era
of stenting (average mortality 1.06%; ptrend  0.273).
Mainly because of a combined decrease in CABG and MI
rates, as well as a decrease in the inability to cross or engage
lesions, the clinical success rate for men increased by 5.95%
to 94.2% in 1998 to 1999.
For most of the study period, the CABG rates in women
were slightly higher than those in men, driven by differences
in the need for emergency CABG. However, by 1998–
1999, the rates of emergency CABG converged, and there
was no longer a significant difference in overall CABG rates
(OR 1.34, 95% CI 0.76 to 2.38; p  0.315). On average,
over the entire period of study, the MI rates were not
discernibly different in women versus men (OR 1.02, 95%
CI 0.85 to 1.24; p  0.810), and there were no significant
difference in rates when each period was examined sepa-
rately (e.g., for 1998 to 1999, OR 1.18, 95% CI 0.84 to
1.68; p  0.339). The average mortality rate during this
period was slightly higher for women (1.21%) than for men
Table 3. Unadjusted Rates of In-Hospital Outcomes of Women and Men Undergoing a PCI in
Northern New England by Era of Stenting
In-Hospital
Outcome
Stent Era
ptrend
Early
(1994–6/95)
Provisional
(7/95–1997)
Current
(1998–1999)
Clinical success (%)
Women 89.22 91.12 92.49  0.001
Men 89.28 91.68 94.05  0.001
MI (%)
Women 2.34 1.75 1.93 0.005
Men 1.93 2.05 1.39 0.002
Any CABG (%)
Women 3.55 2.16 1.06  0.001
Men 3.20 1.56 0.82  0.001
Emergent CABG
Women 2.38 1.60 0.63  0.001
Men 2.21 1.09 0.55  0.001
Nonemergent CABG
Women 1.17 0.56 0.43  0.001
Men 0.98 0.47 0.27  0.001
Death (%)
Women 1.47 1.54 1.43 0.568
Men 0.94 1.06 0.79 0.453
CABG  coronary artery bypass graft surgery; PCI  percutaneous coronary intervention.
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(1.06%), although the difference did not reach statistical
significance (OR 1.24, 95% CI 0.96 to 1.60; p  0.096).
The same was true when the analysis was confined to any
period, including the more current era (OR 1.49, 95% CI
0.94 to 2.35; p  0.086) in which the absolute difference in
mortality rates was quite small (0.25%).
DISCUSSION
As the practice of PCI has evolved over the last decade,
outcomes in women in Northern New England have im-
proved, despite an ever-sicker patient population undergo-
ing the procedure. The major changes were decreases in
both the need for CABG (emergent and nonemergent) and
the incidence of postprocedural MI, resulting in improved
clinical success. Almost identical changes were noted for
men. The most current data (1998 to 1999) show no
gender-related differences in the rates of post-PCI CABG
or MI. Mortality rates changed little over the second half of
the decade, and there was not a statistically significant
difference in mortality between women and men, even in the
current era. In fact, an interaction term for gender and year
was not significant for any adverse outcome.
Outcomes in women versus men. Although the average
crude mortality rate for women was higher than that for men
(1.52% vs. 0.89%, p  0.001), the adjusted rate was much
more comparable and not significantly different (1.21% vs.
1.06%; OR 1.24, 95% CI 0.96 to 1.60; p  0.096). Some
investigators have attributed much of the higher mortality rate
seen in women after coronary revascularization to their rela-
tively smaller size (3,8,25–27). Mechanistically, body size has
been associated with vessel size (28,29) and, in turn, small
vessel size with an increased likelihood of post-PCI complica-
tions (30–32). Even when corrected for body size, vessels in
women may be smaller than those in men (33). When we did
not adjust for BSA, postprocedural mortality differed between
women (1.31%) and men (1.00%), and the difference was
significant (OR 1.36, 95% CI 1.08 to 1.71; p  0.009).
Controlling for BSA reduced the mortality difference and
made it statistically insignificant.
What have others reported for post-PCI outcomes in
women in recent years? Mehilli et al. (34) published data on
4,264 consecutive patients who underwent PCI with stent
placement at two referral centers in Germany from 1992 to
1998. The crude mortality rate at 30 days was 1.7% for
women and 0.8% for men (p  0.02). The adjusted hazard
ratio at 30 days for death plus MI was 2.02 (95% CI 1.27 to
3.19). Vessel size was included in the multivariate analysis,
but proved not to be a predictor of the combined 30-day
outcome. The National Cardiovascular Network Registry
reported outcomes of 109,708 procedures performed at 22
selected centers from 1994 to 1997 (35). The stent rate
during this period was 37% for women and 40% for men.
Although the unadjusted in-hospital mortality rate for
women (1.8%) was higher than that for men (1.0%; p 
0.001), the adjusted OR of 1.07 (95% CI 0.92 to 1.24) was
insignificant. Women did have higher rates of Q-wave MI
(OR 1.25, 95% CI 1.1 to 1.4) and repeat revascularization
(OR 1.13, 95% CI 1.1 to 1.2). In contrast, Watanabe and
Ritchie (36) used a 1997 sample of hospital discharge
abstracts to identify 118,549 patients from 21 states who
underwent PCI. Regardless of whether the procedure was
peri-infarction or involved a stent, women had a higher
post-PCI mortality than did men, with ORs ranging from
1.30 to 1.65 (depending on the patient population). Post-
Table 4. Adjusted* Rates of In-Hospital Outcomes of Women and Men Undergoing a PCI in
Northern New England by Era of Stenting
In-Hospital
Outcome
Stent Era
ptrend
Early
(1994–6/95)
Provisional
(7/95–1997)
Current
(1998–1999)
Clinical success (%)
Women 89.03 91.45 93.45  0.001
Men 88.25 91.23 94.20  0.001
MI (%)
Women 2.44 1.76 1.71 0.378
Men 2.18 2.09 1.36 0.009
Any CABG (%)
Women 3.39 2.10 0.94  0.001
Men 3.32 1.66 0.83  0.001
Emergent CABG
Women 2.20 1.54 0.60  0.001
Men 2.15 1.14 0.55  0.001
Nonemergent CABG
Women 1.08 0.50 0.38  0.001
Men 1.04 0.52 0.28  0.001
Death (%)
Women 1.36 1.30 1.04 0.846
Men 1.14 1.27 0.79 0.273
*See Appendix A for list for regression models.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PCI  percutaneous coronary intervention.
2098 Malenka et al. JACC Vol. 40, No. 12, 2002
PCI Outcomes by Gender in 1994 to 1999 in Northern New England December 18, 2002:2092–101
procedural CABG rates were higher for women than for
men in patients receiving a stent, regardless of the indication
(OR 1.26 for peri-infarction; OR 1.55 for other indication),
but were comparable after PCI in nonstented patients.
Using another administrative data set—a national sample of
1996 Medicare data—Wennberg et al. (37) also reported
increased in-hospital post-PCI mortality for women com-
pared with men (OR 1.25; p  0.001). Recent studies from
several other large registries have reported only on data
collected through 1994 (38–40), before the widespread
availability of stents.
Temporal changes in outcomes. The decrease in CABG
and MI rates that we saw paralleled the temporal growth in
the use of coronary stents (Fig. 1). We suspect, as others
have found (41), that the availability of stents allowed
interventionists to better cope with suboptimal results and
to avoid abrupt closures. In a multivariate model, stent use
was associated with a decreased risk of postprocedural
CABG (OR 0.31, 95% CI 0.26 to 0.37). It was not
associated with a reduction, or increase, in the clinical
postprocedural MI rate (OR 1.12, 95% CI 0.97 to 1.29), as
we defined it.
The availability of coronary stents may not be the only
factor responsible for the temporal decrease in adverse
outcomes. Improvements in guiding catheters, wires, and
balloon catheters may have increased the likelihood of
procedural success by facilitating the crossing of lesions
and/or their engagement. The increased use of a rotational
atherectomy device may have resulted in more success with
calcified and fibrotic lesions. The physicians’ cumulative
experience with PCI increased over the study period and
may have led to improved clinical judgment in patient
selection and procedural decisions. Recent trials (42,43)
have found the routine use of GP IIb/IIIa inhibitors
improved post-PCI outcomes, regardless of gender (44). It
is unlikely that the use of GP IIb/IIIa inhibitors contributed
much to our findings. The use of these agents was largely
confined to 1998 to 1999, which antedates the gradual
decline in CABG we observed, and the presence of these
agents was actually associated with an increased risk of MI
in these data, suggesting a possible selection bias in their
use.
It is not clear why mortality rates did not fall over time.
Decreasing the rates of CABG and MI might be expected
to lead to a reduction in postprocedural mortality. However,
14% of deaths occurred after CABG or MI, and the
case-fatality rate remained relatively constant over time.
There was an increase over time in the complexity of the
lesions being attempted. Although this could be a conse-
quence of coding “creep,” it might also mean that physicians
were attempting more complex lesions and that, despite the
availability of stents and adjuvant therapy, patients were
getting into trouble. In previous work (45), we showed that
only half of all deaths after PCI could, in some way, be tied
to a technical complication of the procedure. The other half
were due to preexisting acute cardiac disease, progression of
chronic cardiac disease, or noncardiac disease. Welty et al.
(46) also reported a high incidence of noncardiac death after
PCI, which, interestingly, was 16-fold greater in women
than in men. Even if mortality due to technical complica-
tions was falling, intervening in a higher percentage of
patients with disease processes that directly relate to death
could obscure any decreasing procedure-related mortality,
resulting in no apparent change in death rates over time.
Although we can control for the presence of many co-
morbid conditions that increase the risk of dying, we cannot
necessarily control for their severity. The same could be said
of our measures of patient acuity, though repeating analyses
after excluding patients requiring an emergent procedure
did not change our results. Even a large study could be
underpowered to detect a change in mortality rates. This is
unlikely in our study, because when comparing the first half
of the study period to the latter, we had 95% power to detect
a 50% decrease in mortality rates for women, with an alpha
level of 0.05.
Other registries have also found little change in mortality
over time. The National Cardiovascular Network PCI data
base (47) reported an overall mortality rate of 1.3% in 1994
through 1997, with no significant change in mortality over
the study period. The National Heart, Lung, and Blood
Institute’s Dynamic Registry of PCI reported no change in
mortality rates between 1985 to 1986 (1.9%) and 1997 to
1998 (1.4%) (48). However, using 1996 to 1998 data from
the Society for Cardiac Angiography and Interventions
Registry, Kimmel et al. (41) reported an overall mortality
rate of 0.5%—half the rate seen in Northern New England.
In that analysis, patients undergoing a graft PCI or in whom
a device was used were removed from the analysis. Remov-
ing these patients from our analysis still resulted in an
overall mortality rate of 1%. Data from the Society
Registry were not validated, and it is possible that under-
reporting of adverse events explains the lower death rate in
their study cohort.
Study limitations. There are several limitations to our
study. We report on a regional experience in the Northeast,
which has a more conservative practice pattern than other
areas of the country (49), possibly limiting the generaliz-
ability of our results. However, the characteristics of our
patients and our rate of stenting are comparable to other
reports (30,48,49). Perhaps more relevant to the issue of
generalizability is the fact that all our operators and all our
institutions in Northern New England met criteria for being
“high volume,” which is not true of other regions of the
country (50). As we (51,52) and others (53) have reported,
there is an inverse relationship between volume and PCI
outcomes, so our results in Northern New England may be
better than can be expected elsewhere. Myocardial infarc-
tion was not a validated outcome, and it is possible that our
point estimates of this event may be too conservative.
However, in another study of data collected in the early
1990s (54), a chart-based review of our data demonstrated
no under-reporting of MIs, as we defined them. We cannot
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comment on gender-related or temporal changes in asymp-
tomatic elevations in cardiac enzymes, as this information
was not collected. Finally, as with any observational study,
uncontrolled confounding could have affected our analysis
of differences in outcomes between women and men or of
changing outcomes over time, although we did use standard
patient and disease characteristics to try and eliminate this
possibility (55).
Conclusions. There has been concern in the cardiology
community that cardiac care for women has been inferior to
that for men. In this study, we demonstrated that as the
practice of PCI has evolved over the mid to late 1990s,
outcomes for women have improved. Women do present
somewhat differently than do men, and we cannot comment
on whether this relates to the biology of the disease or to
bias in recognizing the disease, or both. Once the decision
is made to proceed with PCI, outcomes for women are good
and comparable to those in men after adjusting for baseline
differences in presentation and co-morbidities. Of particular
importance is the recognition that because women, on
average, are smaller than men and because body size relates
to procedural outcome, women, on average, will have a
slightly higher adverse event rate than will men. However,
once we adjust for body size, the event rates are comparable.
Based on these insights, PCI should be considered a viable
option for women. In addition, regardless of gender, inter-
ventionists should pay particular attention to procedural
details such as sheath size, choice of device and its size,
dosing of drugs, and access site care in all patients with a
small BSA. The future will continue to bring innovations in
the practice of percutaneous coronary revascularization, and
observational studies such as ours will continue to be needed
so that patients and practitioners are provided with the best
of information to make their medical decisions.
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APPENDIX
Logistic Regression Models for
Each Outcome Variable
1. In-hospital death: age, BSA, creatinine 2 mg/dl, ejec-
tion fraction, LVEDP, indication, emergency priority,
thrombolysis, preprocedural intra-aortic balloon pump,
preprocedural intravenous nitroglycerin, and ACC type
C lesion.
2. CABG: age, BSA, DM, previous MI, previous PCI,
previous CABG, emergency priority, number of diseased
coronary arteries, PCI of the proximal left anterior
descending coronary artery, and ACC type B2 or C
lesion.
3. Emergency CABG: age, BSA, DM, previous CABG,
previous PCI, emergency priority, number of diseased
coronary arteries, proximal left anterior coronary artery
lesion, and ACC type C lesion.
4. Nonemergency CABG: BSA, DM, previous MI, previous
PCI, indication, number of diseased coronary arteries,
preprocedural heparin, and ACC type B1, B2, or C lesion.
5. MI: BSA, LVEDP, preprocedural heparin, number of
diseased coronary arteries, graft PCI, and ACC type B1,
B2, or C lesion.
6. Clinical success: age, BSA, DM, creatinine 2 mg/dl,
indication, emergent priority, number of diseased coro-
nary arteries, LVEDP, graft PCI, and ACC type B1, B2,
or C lesion.
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